Myosin Therapeutics to Showcase Innovative Cancer Approaches at BioFuture 2026 in NYC
Myosin Therapeutics, a clinical-stage biotechnology firm based in Jupiter, Florida, has made headlines with its recent invitation to present at the BioFuture 2026 conference, scheduled for October 27-28 in New York City. This significant opportunity arises as the company has been selected as a featured company in the National Cancer Institute's (NCI) SBIR Investor Initiatives showcase for the 2026-2027 period. At the conference, Courtney Miller, PhD and CEO of Myosin Therapeutics, will contribute to a panel discussion titled "Beyond the Cure: The Brave New World of Revolutionary Cancer Therapeutics." This panel will bring together various leaders from the biotechnology sector to explore innovative strategies and technologies influencing the future of oncology.
Miller will be joined by Karen Smith, MD, PhD, MBA, LLM, the Chief Medical Officer, who will engage with potential investors and strategic partners throughout the event. The panel discussion organized at BioFuture aims to delve into cutting-edge treatments in cancer care, including advanced therapeutic platforms, AI-driven drug discovery, and precision medications. Emerging methods, particularly those focusing on next-generation cell therapies, will also be scrutinized.
"Glioblastoma serves as a proving ground for a novel cancer treatment methodology that targets the physical mechanics of cancer cells rather than solely their biochemical signaling pathways," stated Dr. Miller. One of the highlights of Myosin's developments is its leading compound, MT-125, which is making strides toward further Phase 2 studies. The timing of the BioFuture conference is pivotal for Myosin, as they seek investors to support the expansion of MT-125 into two additional treatment-resistant cancers.
MT-125 is a groundbreaking non-muscle myosin inhibitor designed to exploit the mechanical dependencies inherent in cancer cell survival and proliferation, ultimately leading to their death. The FDA has already granted Orphan Drug Designation to MT-125 for malignant gliomas, along with Fast Track Designation specifically for glioblastoma treatment. The groundwork for this innovative approach has been reinforced through two significant publications in the prestigious journal 'Cell'. Furthermore, Myosin Therapeutics is actively enrolling participants in its STAR-GBM clinical trial (NCT07185880) at various Mayo Clinic locations across Florida, Arizona, and Minnesota, targeting newly diagnosed patients with unmethylated MGMT glioblastoma.
BioFuture 2026, produced by Demy-Colton, is a key event that gathers innovators and investors to shape the future of biopharmaceuticals. The event will host over 500 attendees and feature more than 100 speakers along with over 50 presenting companies within its Therapeutic Spotlight Panels and Seed Showcase. It provides a space for one-on-one meetings between potential partners and investors, facilitating connections vital for future development.
Organizations interested in meeting with Myosin Therapeutics can engage through the BioFuture partnering system or directly by emailing the company. As the biotech sector continues to evolve rapidly, Myosin's advancements signify the critical intersection of science and investment, opening new avenues for cancer treatment and patient care.
As the conference approaches, the spotlight remains on Myosin Therapeutics, demonstrating its commitment to innovation in cancer therapy by utilizing unique mechanical insights into tumor biology. The future of oncology lies in the integration of revolutionary treatments, and Myosin's approach epitomizes this transformative journey. The team looks forward to sharing its progress and plans at BioFuture, emphasizing its vital role in addressing some of the most pressing challenges in cancer therapy today.
Miller will be joined by Karen Smith, MD, PhD, MBA, LLM, the Chief Medical Officer, who will engage with potential investors and strategic partners throughout the event. The panel discussion organized at BioFuture aims to delve into cutting-edge treatments in cancer care, including advanced therapeutic platforms, AI-driven drug discovery, and precision medications. Emerging methods, particularly those focusing on next-generation cell therapies, will also be scrutinized.
"Glioblastoma serves as a proving ground for a novel cancer treatment methodology that targets the physical mechanics of cancer cells rather than solely their biochemical signaling pathways," stated Dr. Miller. One of the highlights of Myosin's developments is its leading compound, MT-125, which is making strides toward further Phase 2 studies. The timing of the BioFuture conference is pivotal for Myosin, as they seek investors to support the expansion of MT-125 into two additional treatment-resistant cancers.
MT-125 is a groundbreaking non-muscle myosin inhibitor designed to exploit the mechanical dependencies inherent in cancer cell survival and proliferation, ultimately leading to their death. The FDA has already granted Orphan Drug Designation to MT-125 for malignant gliomas, along with Fast Track Designation specifically for glioblastoma treatment. The groundwork for this innovative approach has been reinforced through two significant publications in the prestigious journal 'Cell'. Furthermore, Myosin Therapeutics is actively enrolling participants in its STAR-GBM clinical trial (NCT07185880) at various Mayo Clinic locations across Florida, Arizona, and Minnesota, targeting newly diagnosed patients with unmethylated MGMT glioblastoma.
BioFuture 2026, produced by Demy-Colton, is a key event that gathers innovators and investors to shape the future of biopharmaceuticals. The event will host over 500 attendees and feature more than 100 speakers along with over 50 presenting companies within its Therapeutic Spotlight Panels and Seed Showcase. It provides a space for one-on-one meetings between potential partners and investors, facilitating connections vital for future development.
Organizations interested in meeting with Myosin Therapeutics can engage through the BioFuture partnering system or directly by emailing the company. As the biotech sector continues to evolve rapidly, Myosin's advancements signify the critical intersection of science and investment, opening new avenues for cancer treatment and patient care.
As the conference approaches, the spotlight remains on Myosin Therapeutics, demonstrating its commitment to innovation in cancer therapy by utilizing unique mechanical insights into tumor biology. The future of oncology lies in the integration of revolutionary treatments, and Myosin's approach epitomizes this transformative journey. The team looks forward to sharing its progress and plans at BioFuture, emphasizing its vital role in addressing some of the most pressing challenges in cancer therapy today.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.